Neos at RBC 2017 Healthcare Conference (Replay)
02/23/17 at 10:30 a.m. ET
Corporate ProfileNeos Therapeutics is focused on developing, manufacturing and commercializing branded products utilizing our proprietary extended-release drug delivery technology platform. We have used this technology to develop our three product candidates being investigated for the treatment of attention deficit hyperactivity disorder, or ADHD. Our ADHD product candidates are extended-release, or XR, medications in patient-friendly, orally disintegrating tablets, or ODT, or liquid suspension dosage forms.
- 02/16/17Neos Therapeutics to Present at the RBC Capital Markets 2017 Global Healthcare Conference
- 02/03/17Neos Therapeutics Announces Pricing of Underwritten Public Offering of $25.0 Million of Common Stock
- 02/02/17Neos Therapeutics Announces Proposed Offering of Common Stock
- 12/20/16Neos Therapeutics Completes Resubmission of NDA for Cotempla XR-ODT for the Treatment of ADHD